Drug Approval | September 24, 2025
Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1
The facility has been classified as Voluntary Action Indicated
The facility has been classified as Voluntary Action Indicated
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Subscribe To Our Newsletter & Stay Updated
